Efficacy and Safety of Biosimilar Ranibizumab (OPTIMAB(®)) versus Innovator Ranibizumab in Patients with Neovascular (Wet) Age-Related Macular Degeneration: A Double-Blind, Randomized, Multicenter, Phase III Study
生物类似药雷珠单抗(OPTIMAB®)与原研药雷珠单抗治疗新生血管性(湿性)年龄相关性黄斑变性患者的疗效和安全性:一项双盲、随机、多中心III期研究
期刊:
影响因子:
doi:10.2147/OPTH.S488866
Rana, Parth J; Deshmukh, Himanshu; Shah, Urmil; Kumar, Vinod; Kanungo, Sanghamitra; Singhal, Deepika; Mahapatra, Santosh Kumar; Vakharia, Ira; Jaiswal, Mukesh; Gondane, Ajitkumar; Vaidya, Pooja; Shahavi, Vinayaka; Shandilya, Harish; Pawar, Dattatray; Sharma, Akhilesh